Mutations in RUNX1 and CEBPA in AML patients can affect the methylation status of key regulatory sites, causing suppression of multiple target genes regulated by these transcription factors, which is likely to be achieved through a TET2-dependent mechanism (24). This evidence concerns the gene RUNX1 and acute myeloid leukemia.